Karen A Tourian

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies
    Karen A Tourian
    Wyeth Research, Paris, France
    Clin Ther 31:1405-23. 2009
  2. ncbi A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder
    Lucia Septien Velez
    Wyeth Research, Paris, France
    Int Clin Psychopharmacol 22:338-47. 2007
  3. ncbi Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials
    Karen A Tourian
    Wyeth, a company of the Pfizer Group, Paris, France
    CNS Spectr 15:187-93. 2010
  4. ncbi Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine
    Karen A Tourian
    Wyeth, a company of the Pfizer Group, Division Wyeth Research, Paris, France
    J Clin Psychopharmacol 30:411-6. 2010
  5. ncbi Desvenlafaxine and weight change in major depressive disorder
    Karen A Tourian
    Wyeth Research, Collegeville, Pennsylvania and Wyeth Research, Paris, France Drs Tourian and Leurent are currently with Wyeth, a company of the Pfizer Group, Paris, France, and Drs Graepel and Ninan are currently with Pfizer Inc, Collegeville, Pennsylvania
    Prim Care Companion J Clin Psychiatry 12:PCC.08m00746. 2010

Collaborators

  • Philip T Ninan
  • Lucia Septien Velez
  • Lucia Septien-Velez
  • Jean Michel Germain
  • Jean-Michel Germain
  • Bruno Pitrosky
  • Sudharshan Krishna Padmanabhan

Detail Information

Publications5

  1. ncbi Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies
    Karen A Tourian
    Wyeth Research, Paris, France
    Clin Ther 31:1405-23. 2009
    ..Although a number of effective antidepressants are available, the need for new medications that are effective and well tolerated remains...
  2. ncbi A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder
    Lucia Septien Velez
    Wyeth Research, Paris, France
    Int Clin Psychopharmacol 22:338-47. 2007
    ..These data provide support for the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder...
  3. ncbi Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials
    Karen A Tourian
    Wyeth, a company of the Pfizer Group, Paris, France
    CNS Spectr 15:187-93. 2010
    ..This analysis evaluated the effects of the serotonin-norepinephrine reuptake inhibitor, desvenlafaxine (administered as desvenlafaxine succinate), on anxiety symptoms associated with depression...
  4. ncbi Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine
    Karen A Tourian
    Wyeth, a company of the Pfizer Group, Division Wyeth Research, Paris, France
    J Clin Psychopharmacol 30:411-6. 2010
    ..No evidence of a signal for increased suicidality was detected in adult patients treated with desvenlafaxine in short-term MDD trials. As suicidal events were extremely rare, a true increased risk cannot be ruled out...
  5. ncbi Desvenlafaxine and weight change in major depressive disorder
    Karen A Tourian
    Wyeth Research, Collegeville, Pennsylvania and Wyeth Research, Paris, France Drs Tourian and Leurent are currently with Wyeth, a company of the Pfizer Group, Paris, France, and Drs Graepel and Ninan are currently with Pfizer Inc, Collegeville, Pennsylvania
    Prim Care Companion J Clin Psychiatry 12:PCC.08m00746. 2010
    ..To characterize weight change during short- and longer-term treatment with desvenlafaxine (administered as desvenlafaxine succinate) for major depressive disorder (MDD)...